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Abstract
Background: Both vitamin D and iron deficiencies are widespread globally, and a relationship between these
deficiencies has been suggested. However, there is a paucity of randomised controlled trials assessing the effect of
vitamin D supplementation on iron status.
Purpose: We aimed to investigate whether 16 weeks of daily vitamin D3 supplementation had an effect on serum
ferritin, haemoglobin, serum iron and transferrin saturation.
Methods: Overall, 251 participants from South Asia, Middle East and Africa aged 18–50 years who were living in Norway
were randomised to receive daily oral supplementation of 10 μg vitamin D3, 25 μg vitamin D3, or placebo for 16 weeks
during the late winter. Blood samples from baseline and after 16 weeks were analysed for serum 25-hydroxyvitamin D
(s-25(OH) D), serum ferritin, haemoglobin and serum iron. In total, 214 eligible participants completed the intervention
(86 % of those randomised). Linear regression analysis were used to test the effect of vitamin D3 supplementation
combined (10 or 25 μg) and separate doses 10 or 25 μg compared to placebo on change (T2-T1) in each outcome
variable adjusted for baseline s-25(OH)D values.
Results: There was no difference in change in the levels of s-ferritin (1.9 μg/L, 95 % CI: -3.2, 7.0), haemoglobin (-0.02 g/dL,
95 % CI: -0.12, 0.09), s-iron (0.4 μg/L, 95 % CI: -0.5, 1.3) or transferrin saturation (0.7 %, 95 % CI: -0.6.1, 2.0) between those
receiving vitamin D3 or those receiving placebo. Serum 25-hydroxyvitamin D increased from 29 nmol/L at baseline to
49 nmol/L after the intervention, with little change in the placebo group.
Conclusions: In this population of healthy ethnic minorities from South Asia, the Middle East and Africa who had low
vitamin D status, 16 weeks of daily supplementation with 10 or 25 μg of vitamin D3 did not significantly affect the
haemoglobin levels or other markers of iron status.
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Introduction
Iron deficiency remains one of the most severe and
important nutritional deficiencies in the world. This
deficiency affects more than 30 % of the world’s popula-
tion, thus impacting an estimated 2 billion people [1, 2].
Iron deficiency causes anaemia and disrupts the optimal
function of both the endocrine and immune systems.
Iron homeostasis is strictly controlled by duodenal
enterocytes, which absorb dietary iron; macrophages,
which recycle iron from erythrocytes and other cells and
hepatocytes, which store iron and can release it when
needed [3]. In addition, vitamin D deficiency is wide-
spread, and a high prevalence of vitamin D insufficiency
among non-western immigrant populations living in
Western countries has been reported [4–8].
A co-existence of vitamin D and iron deficiencies has
been reported, and an association between low serum
25-hydroxyvitamin D (s- 25(OH) D) and low levels of
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serum iron (s-iron), low erythrocyte values and transfer-
rin saturation has been found in cross-sectional studies
[9–12]. One study found that 92 % of iron-deficient
Spanish women aged 18–35 years also had vitamin D
deficiency or insufficiency (defined as an s- 25(OH)D
concentration of <50 nmol/L or 51–74 nmol/L respect-
ively) [13]. In addition, an inverse association between
iron status and bone resorption in young menstruating
women has been reported [14, 15].
The possible mechanism of these associations could in-
volve erythrocyte precursor cells that express 1,25-hydroxy-
vitamin D (the active form of vitamin D) receptors, which
induce the proliferation and maturation of erythroid pro-
genitor cells. Therefore, deficiency of 1,25-hydroxyvitamin
D may affect erythropoiesis [16–18].
It has also been documented that hepcidin regulates
the absorption, tissue distribution, and extracellular
concentration of iron by suppressing the ferroportin-
mediated export of cellular iron [19, 20]. Vitamin D is a
potent regulator of the hepcidin-ferroportin axis there-
fore, vitamin D deficiency may affect the regulation of
hepcidin, which could accelerate the decrease in haemo-
globin and increase the incidence of anaemia [21, 22].
In Norway, vitamin D deficiency is far more prevalent
among immigrants than among ethnic Norwegians, and
more than one-third of immigrants from the Middle East,
Sub-Saharan Africa and South Asia have 25(OH)D below
25 nmol/L [4, 5, 23, 24]. Currently, aside from the results
of small studies conducted among Pakistani pregnant
women and children in the 1990s, which found a high
prevalence of iron deficiency, there are no data on iron
status among immigrant populations in Norway [25–27].
Although observational studies have suggested a rela-
tionship between these deficiencies, there is a paucity of
randomized controlled trials (RCTs) assessing the effect
of vitamin D supplementation on iron status. However,
in a small randomised, placebo-controlled trial, Indians
aged 15 to 60 years with concurrent iron-deficiency
anaemia and vitamin D deficiency anaemia received vita-
min D3 intramuscularly, but the vitamin D supplement
did not improve haemoglobin concentrations [28]. The
trial was small and non-conclusive, and other studies
were cross-sectional.
In addition, randomised studies that examined the effect
of vitamin D on iron status in the general immigrant
population have not been conducted. We therefore
present here results for the predefined additional objective
of our previously reported randomised, double-blind,
placebo-controlled trial on the effect of vitamin D supple-
mentation on muscle strength and power among ethnic
minorities in Norway [29]. We hypothesised that improv-
ing the low vitamin D status in immigrants would posi-
tively affect their iron status. The aim of the present study
was to determine whether 16 weeks of daily vitamin D3
supplementation (10 or 25 μg/d) vs placebo would affect
the iron status (serum ferritin, haemoglobin, s-iron, and
transferrin saturation) in a multi-ethnic immigrant popu-
lation during the late wintertime.
Materials and methods
The study subjects were healthy men and women aged
18–50 years who were born or whose parents were born
in the Middle East, Africa or South Asia. The subjects
were recruited from 11 different community centres in
Oslo and the surrounding areas (at latitude 60°N). The in-
clusion criteria included not pregnant, non-breastfeeding,
not regularly using vitamin D-containing supplements,
not being treated for vitamin D deficiency, not using
medication that interfered with vitamin D metabolism
(thiazides, anti-epileptics, prednisolone or hormone re-
placement therapy), and not suffering from any condition
such as malabsorption, kidney diseases, cancer, tubercu-
losis, sarcoidosis, osteoporosis or recent fractures. All of
the female participants were younger than 50 years old
(when menopause normally starts), but they were not
asked about menopausal status or the current use of oral
contraception. The same data collection team visited all of
the centres and performed the baseline and follow-up data
collection. Interpreters were used when necessary, but the
majority of the study participants were able to communi-
cate in the Norwegian language.
Randomisation and intervention
The 16-week intervention study was carried out from
January to June 2011. Those who fulfilled the eligibility
criteria were randomly assigned to one of three equally
sized intervention groups receiving one tablet per day
containing 25 μg vitamin D3, 10 μg vitamin D3 or placebo.
The tablets were similar in colour, size and packing. Each
participant was given a box containing 120 tablets (a 16-
week use corresponds to 112 tablets) at baseline along
with a self-administered compliance form. The tablets
were manufactured by Bio Plus Life Sciences PVT LTD,
DMA (Bangalore, India), which is certified for Good
Manufacturing Practice, and the ingredients met the re-
quirements of British Pharmacopé. If the study subjects
forgot to take a tablet on one day, they were asked to take
two tablets on the following day. Participants were
followed up with a short text message twice a week to re-
mind them to take the tablets. Subjects were advised to
maintain their usual dietary pattern during the 16-week
trial period and were advised to contact the study staff by
telephone if they had any queries.
Main outcome variables
The study outcomes included the changes in the following
status during the 16-week intervention between the
pooled intervention groups (10 or 25 μg of vitamin D3/d)
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and the placebo group: s-ferritin, haemoglobin, s-iron and
transferrin saturation.
Random allocation
We chose a computer-generated block randomisation
method to ensure a good balance between the number of
individuals in each group during the trial and randomly
varied the block size between 3 and 6.
Blinding
Group allocation was unknown to participants, research
staff, investigators, and data collectors. The tablet boxes
were numbered according to the randomisation list by
an external pharmacy (the Hospital Pharmacy at Oslo
University Hospital). The group allocation list was stored
at this pharmacy with a copy of the list in a sealed enve-
lope. Each participant was consecutively numbered and
received a pre-packaged tablet box with the correspond-
ing number.
Registration and ethics approval
The study was authorised as a clinical trial by the Norwe-
gian Medicine Agency and was approved by the Regional
Committee for Medical and Health Research Ethics (study
code: 2010/1982). All participants gave written informed
consent. The study has been registered at EudraCT (2010-
021114-36). The clinical trial was conducted according to
the principles of the Declaration of Helsinki and in
accordance with national laws. Clinical Trials.gov identi-
fier NCT01263288.
Blood sampling and analyses
Non-fasting venous blood was drawn at baseline and after
16 weeks. To obtain serum, blood was collected in serum-
separator gel tubes and was centrifuged after 30 min to
2 h. To collect plasma, blood was collected in EDTA-
tubes and centrifuged within 30 min at room temperature
at the study site. Serum and plasma were separated and
frozen in several aliquots at -20 °C on the same day as
sample collection and were transferred at intervals of 1–
2 weeks to -80 °C storage until the samples were analysed.
After the completion of the study, all serum samples
from baseline and follow-up were analysed in one batch
at Fürst Medical Laboratory (www.furst.no), which is
accredited by the International Organization for Stand-
ardisation and is part of the vitamin D quality assess-
ment scheme (DEQAS). Serum 25-hydroxyvitamin D
(25(OH) D) was measured using high-pressure liquid
chromatography tandem mass spectrometry (HPLC-
MS-MS) with the Waters Acquity UPLC and Waters
triple quadrupole MS instruments. In house standards
at four levels ranging from 25–200 nmol/L were cali-
brated against external MS-standards from Recipe
(Germany), product no. MS7013, traceable to National
Institute of Standards and Technology (NIST). A deu-
terised internal standard with C26,27 hexadeuterium-
labelled 25(OH) D3, which was purchased from Synthe-
tica (Norway), was used to calculate both 25(OH) D2
and 25(OH) D3. The CV (reproducibility within the la-
boratory, 4 instruments) for serum 25(OH) D3 was 8 %
at a concentration of 55.2 nmol/L and 6 % at a concen-
tration of 195.1 nmol/L. In the analysis, the term
25(OH)D is used for the sum of 25(OH) D2 and –D3,
but we note that the contribution of 25(OH)D2 was
negligible.
Haemoglobin was measured using SYSMEX, which uti-
lises the non-cyanide reagent, sodium lauryl sulfate (SLS).
S-ferritin was analysed using an immunoturbidimetric
method, and the total iron binding capacity (TIBC) was
calculated (TIBC (μmol/L) = 25.1 × Transferrin (g/L). S-
iron was measured by colorimetric assays using Ferrozine.
Transferrin saturation (%) was calculated as (iron/TIBC) x
100. Serum folic acid and serum vitamin B12 levels were
measured using the Centaur XP system from Siemens.
The interassay coefficients of variation were 1.7 %
(haemoglobin), 2.3 % (ferritin), 2.0 % (TIBC), 2.7 % (iron),
8.2 % (folic acid) and 7.4 % (vitamin B12). C-reactive pro-
tein (CRP), which is a marker of inflammation in the body,
was measured (reference < 5 mg/L).
Anaemia was defined as a haemoglobin concentra-
tion of < 12 g/dL for women and <13 g/dL for men.
Iron deficiency anaemia (IDA) was defined as a haemo-
globin level of <12 g/dL and s-ferritin of <15 μg/L for
women and a haemoglobin level of <13 g/dL and s-
ferritin of <15 μg/L for men [30, 31]. The s-ferritin
level is the most specific biochemical test that corre-
lates with total body iron stores and has been used as a
key parameter in several epidemiological studies to as-
sess iron status [32]. Transferrin saturation (TS) is an
indication of the ability to bind iron and transport it to
various sites such as the bone marrow or liver and
serum iron and TIBC are needed to calculate the TS %.
We want to include TS and TIBC to capture any sus-
pect of iron disorders (deficiency or overload). Vitamin
B12 deficiency frequently causes macrocytic anemia
and folate deficiency is characteristically associated
with macrocytosis and megaloblastic anaemia. We
have recently reported that vitamin D deficiency and
secondary hyperparathyroidism (SHPT) is prevalent
among non-western immigrants in Norway, it also
documented that marrow fibrosis has been reported in
cases of primary and secondary hyperparathyroidism
with very high levels of PTH.
Statistical analyses
The sample size was planned for an effect of the inter-
vention on muscle strength and power. The results from
the primary endpoint have previously been reported [29]
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and here we present results from predefined additional
endpoints. The sample calculation suggested that we in-
clude 210 participants; thus, under the assumption of an
expected dropout rate of 15–20 %, we aimed to recruit
at least 250 participants. Statistical analysis of the data
was performed using the IBM SPSS statistical software
(V.19.0; SPSS Inc, Chicago, Illinois, USA). For each of
the outcome variables, we calculated the difference in
change from baseline to follow-up between the com-
bined/pooled intervention groups (10 or 25 μg/day) and
the placebo group. These findings were analysed using
linear regression analysis, where the effect on each out-
come variable was adjusted for the respective baseline
concentration. The same analysis as described above was
performed to compare 25 μg/day to placebo and 10 μg/
day to placebo separately. P values of <0.05 were consid-
ered statistically significant. Subgroup analyses by base-
line values of end point measures, gender, and
intervention dose were also performed. The effect esti-
mates for each outcome variable are the change from
baseline to 16 weeks.
Results
301 persons were assessed for eligibility of the study
and 251 persons fulfilled the inclusion criteria the par-
ticipation rate was 83 % and did not differ by ethnicity.
A total of 251 study participants were randomly
assigned to one of the three interventions. After 16
weeks, 214 (85 %) study participants completed the
study (Fig. 1). Participant characteristics are shown in
Table 1. No substantial between-group differences in
baseline values were noted (Table 1). The baseline char-
acteristics of the 37 participants who did not complete
the study were not different from those who completed
the study (Additional file 1: Table S1). Although the
study participants originated from 11 different coun-
tries in the Middle East, Sub- Sahara Africa and South
Asia, persons with Somali (n = 97) and Tamil back-
ground were the majority (n = 71).
Baseline characteristics
The mean baseline s-25(OH)D concentration for the
whole study population was 29 (SD 17.6) nmol/L. Around
Fig. 1 Flow chart of recruitment, randomization and follow-up
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Table 1 Baseline characteristic for the 251 participants who completed the baseline testsa
25 μg Vitamin D3 10 μg Vitamin D3 Placebo
N = 84 N = 85 N = 82
Age (years) 36.4 (8.2) 37.0 (7.6) 38.5 (7.6)
Gender, female N (%) 58 (69) 61 (72) 63 (77)
Region of origin N (%)
South Asia 31 (37) 31 (36) 33 (40)
Middle East and North Africa 15 (18) 9 (11) 12 (15)
Sub-Sahara Africa 38 (45) 45 (53) 37 (45)
Body mass index 27.0 (5.2) 27.5(5.2) 27.8 (5.0)
Female 27.7 (5.3) 27.7 (5.3) 28.9 (5.0)
Male 25.0 (4.6) 26.3 (3.0) 24.5 (3,3)
S- 25(OH)D (nmol/L) 26.9 (16.4) 29.7 (20.5) 30.0 (19.0)
Female 26.6 (17.3) 30.8 (22.3) 30.6 (19.8)
Male 27.5 (14.6) 26.9 (15.2) 28.6 (16.2)
Hemoglobin (g/dL)b 13.6 (1.6) 13.7 (1.6) 13.6 (1.4)
Female 12.8 (1.2) 13.1 (1.4) 13.0 (0.9)
Male 15.2 (0.9) 15.1 (1.2) 15.5 (0.8)
Serum iron (μg/L)c 14.4 (6.6) 14.3 (5.7) 13.1 (5.7)
Female 12.5 (5.5) 13.6 (5.8) 12.0 (5.4)
Male 18.6 (6.8) 15.8 (5.3) 16.9 (4.9)
Serum ferritin (μg/L)c mean (SD) 58.9 (62.8) 81.6 (88.8) 56.3 (63.2)
Female 33.1 (38.8) 46.4 (40.5) 34.1 (41.6)
Male 116.7 (68.2) 171.4 (113.3) 129.6 (68.2)
Serum ferritin (μg/L) median (IQR)
Female 22 (9.5–46.8) 36 (21–59) 24 (10–34.0)
Male 104 (61–168) 145 (102–219) 110 (82–153)
Transferrin saturation (%)d 20.8 (10.4) 21.5 (9.3) 18.4 (8.4)
Female 17.6 (8.8)) 20.7 (10.0) 16.5 (7.8)
Male 27.7 (10.3) 23.4 (7.4) 24.9 (6.4)
S-Total iron binding bapacity (μmol/L)c 72.1 (11.8) 68.6 (10.9) 72.9 (10.8)
Female 74.0 (12.3) 68.9 (11.3) 74.3 (10.9)
Male 67.6 (9.3) 67.5 (9.9) 68.3 (9.4)
S-Folic acid (nmol/L)c 14.8 (6.2) 15.9 (6.6) 15.8 (5.8)
Female 15.5 (6.6) 15.3 (6.0) 15.9 (6.0)
Male 13.4 (5.3) 17.8 (7.9) 15.6 (4.7)
S-Vitamin B12 (pmol/L)c 321.6 (92.7) 343.9 (116.8) 339.9 (105.5)
Female 334.1 (93.8) 359.2 (119.8) 334.1 (110.9)
Male 293.8 (85.9) 300.7 (98.6) 361.4 (82.1)
Plasma PTH (pmol/L)
Female 7.3 (3.1) 7.5 (3.8) 8.5 (4.3)
Male 8.0 (3.6) 6.8 (2.4) 6.3 (2.6)
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90 and 53 % of the participants had an s-25(OH)D of <50
and s-25(OH)D of <25 nmol/L respectively. The mean
baseline haemoglobin concentration for the study popula-
tion was 13.7 (SD 1.5). In the sample, approximately 14 %
(n = 21) of females and 5 % (n = 3) of males had anaemia,
while 29 % (n = 45) of females and 4 % (n = 2) of males
had low serum ferritin values (<15 μg/L) values. Fur-
thermore 10 % (n = 16) of females and none of the
males had iron deficiency anaemia. There were no signifi-
cant correlations between the baseline levels of s-25(OH)D
and s-ferritin (r = 0.06), haemoglobin (r = 0.04), transferrin
saturation (r = -0.004) or s-iron (r = -0.05). CRP values
were generally low, but approximately 23 % of the subjects
had a CRP > 5 mg/L. All of the participants had normal s-
vitamin B12 and s-folic acid levels (Table 1).
Effect of vitamin D supplementation on endpoint
measures
Vitamin D3 supplementation (10 or 25 μg combined
compared to placebo) for 16 weeks had no statistically
significant effects on s-ferritin, haemoglobin, s-iron, or
transferrin saturation (Table 2).
Effects of vitamin D supplementation on serum 25(OH) D,
folic acid and vitamin B12, CRP
As previously reported [29], following the intervention,
the mean s-25(OH)D levels increased by a mean of 17
and 26 nmol/L for the 10 μg and 25 μg vitamin D3
groups, respectively, compared to placebo (Table 2).
There was no change in s-vitamin B12 and s-folic acid
levels as a result of vitamin D supplementation (Table 2).
As previously reported ([33]) there was no difference in
change of s-CRP (mean difference: 0.09 mg/L (95 % CI:
− 1.1, 1.4, P = 0.9)).
We also analysed the effect of the two interventions
(10 and 25 μg) separately, and none of the dosages had a
significant effect on the iron status (Table 3). Vitamin D3
supplementation had also no effect on s-folic acid and s-
vitamin B12 levels.
Additional analyses
We have conducted analysis in the sub-group with an-
aemia and vitamin D3 supplementation had no effect on
iron status. Additional analyses resulted in similar find-
ings that were independent of whether the baseline con-
centration of the iron status was above or below the
mean among participants. Also, analyses ignoring the
randomized design, we found no significant associations
between changes in s-25(OH)D and changes in serum
indicators from baseline to 16 weeks in the total study
population (data not shown). The results were also con-
sistent after stratification of the data by gender, region of
origin or a parathyroid hormone (PTH) greater than the
reference value (data not shown).
Compliance
Compliance with supplementation was confirmed by
counting the number of tablets in the returned tablet
boxes, where 80 % had consumed more than 80 % of the
tablets and 69 % had consumed more than 90 % of the
tablets.
Discussion
The present study showed that 16 weeks of daily vitamin
D3 supplementation (10 or 25 μg) to healthy ethnic mi-
norities did not significantly affect serum ferritin,
haemoglobin, s-iron or transferrin saturation. To our
knowledge, this is the first randomised controlled trial
studying the effect of vitamin D supplementation on
iron status in a presumed healthy immigrant population.
We found that at baseline, 14 % of females and 5 % of
males had anaemia, whereas a third of females and 4 %
of males had depleted iron stores. Furthermore, 90 % of
the study subjects had a 25(OH)D concentration of
<50 nmol/L. At baseline the mean s-25(OH)D among
the 21 females with haemoglobin below 11 g/dL was
23.7 nmol/L which is not so much different for the levels
of s-25(OH)D in the whole study population. However,
the vitamin D3 supplementation for 16 weeks had no
statistically significant effects on haemoglobin or any of
other endpoints in this small group with iron deficiency.
New insights into the biologic functions of vitamin D
have led to increased interest in the clinical conse-
quences of vitamin D deficiency. In addition, a number
of cross-sectional studies have demonstrated an associ-
ation between low 25-hydroxyvitamin D levels and poor
Table 1 Baseline characteristic for the 251 participants who completed the baseline testsa (Continued)
S-CRP (mg/L)e
All 4.9 (6.5) 4.0 (5.5) 4.2 (7.7)
All (median, IQR) 1.8 (0.8–6.7) 1.8 (0.9–4.0) 2.0 (0.8–4.0)
aData are mean (SD) unless specified otherwise
bN = 209
cReference range; s-ferritin (women and men > 16 years 15 -200 and 20 - 300 μg/L respectively), hemoglobin (women and men > 14 years 12–15.3 and 13.4–17), s-
iron (women and men > 18 years 9–34 μmol/L), Transferrin saturation (women < 50 years 10–50 % and men 15–57 %), s-Folic acid >5.7 nmol/L and for s-vitamin
B12 (170–650 pmol/L)
d Iron/TIBC x 100
e Serum C-reactive protein (CRP) included high-sensitivity CRP (hs CRP)
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iron status [9, 11, 13, 34]. To evaluate the prevalence of
anaemia in a population of individuals with vitamin D
deficiency, Sim et al. studied 554 subjects in a general
population over a period of 2 years as part of normal
healthcare operations. Their study demonstrates an asso-
ciation between vitamin D deficiency, a greater risk of
anaemia, lower mean haemoglobin levels, and a higher
use of the erythropoiesis-stimulating agent [9]. These
findings suggested that vitamin D can have an effect on
erythropoiesis, where the 1,25 hydroxyvitamin D hor-
mone plays a role in the proliferation and maturation of
erythroid progenitor cells, therefore, a deficiency of 1,25
hydroxyvitamin D hormone may impair erythropoiesis
[17, 18].
Few studies have evaluated the effect of vitamin D
supplementation on iron status in immigrant popula-
tions. Our findings are in agreement with the results
from a small randomised controlled study in Indians
(n = 30, 15–60 years) with iron-deficiency anaemia who
received one dose of vitamin D3 (0.6 million units intra-
muscularly) and parental iron [28]. Another randomised
placebo-controlled study involved menstruating Spanish
women (n = 109, 18–35 years) who were given iron or
iron along with vitamin D to study the effect on iron
metabolism. The results showed higher values of haem-
atological parameters in the iron plus vitamin D group
compared to the iron only group, indicating that vitamin
D could enhance iron status when taken together with
iron [35].
Furthermore, the role of vitamin D in erythropoiesis
has been suggested by clinical observations. Supplemen-
tation with ergocalciferol has been associated with dose
reductions in erythropoiesis-stimulating agents and in-
creased reticulocytosis in haemodialysis patients [36].
Table 2 Effect of vitamin D supplementation combined (10 μg or 25 μg)a on serum ferritin, hemoglobin, serum iron, Transferrin
Saturation, folic acid and vitamin B12
Baselined After 16 weeks Change from baseline to 16 weeks Difference (95 % CI) compared to placebob P-valuee
S-25(OHD) (nmol/l)
Intervention (n = 143) 28.7 (18.6) 48.8 (19.6) 20.1 (21.7) 21.3 (16.7, 26.0) <0.0001
Placebo (n = 71) 29.2 (15.6) 27.5 (13.7) -1.5 (11.3)
Hemoglobin (g/dL)c
Intervention (n = 136) 13.7 (1.5) 13.5 (1.6) -0.21 (0.6) -0.02 (-0.12, 0.09) NS
Placebo (n = 69) 13.5 (1.4) 13.3 (1.4) -0.27 (0.7)
Serum ferritin (μg/L)
Intervention (n = 143) 68.4 (77.3) 68.0 (85.5) -0.3 (35.7) 1.9 (-3.2, 7.0) NS
Placebo (n = 71) 54.4 (63.2) 51.0 (57.8) -3.4 (19.1)
Serum iron (μg/L)
Intervention (n = 143) 14.4 (5.8) 14.1 (6.1) -0.4 (5.9) 0.4 (-0.5, 1.3) NS
Placebo (n = 71) 13.0 (5.9) 13.5 (6.7) 0.5 (5.9)
Transferrin saturation (%)
Intervention (n = 143) 21.3 (9.4) 20.6 (9.7) 0.5 (8.5) 0.7 (-0.6, 2.0) NS
Placebo (n = 71) 18.3 (8.7) 18.7 (9.5) -0.7 (8.6)
S-Total iron binding capacity (nmol/L)
Intervention (n = 143) 70.3 (11.5) 70.8 (11.5) 0.5 (5.5) -0.08 (-1.0, 0.8) NS
Placebo (n = 71) 73.2 (10.8) 73.5 (11.1) 0.4 (6.1)
S-Folic acid (nmol/L)
Intervention (n = 143) 15.6 (6.9) 15.0 (7.2) -0.5 (5.1) -0.1 (-1.0, 0.7) NS
Placebo (n = 71) 15.8 (5.7) 15.7 (6.0) -0.1 (6.1)
S-Vitamin B12 (pmol/L)
Intervention (n = 143) 334.9 (105)) 323.3 (112.9) -9.1 (64.9) -5.4 (-16.1, 5.3) NS
Placebo (n = 71) 339.9 (105) 337.2 (118.9) -2.7 (67.7)
aThe two intervention groups (10 μg or 25 μg) were combined and compared to the placebo group
bLinear regression was used to compare the changes of outcome variables between intervention and placebo adjusted for baseline level of s-25(OH)D and to cal-
culate the p-value
c N = 205
dData are mean (standard deviation) unless specified otherwise
eApart from s-25(OH) D change from baseline to study end was not significant for any of the parameters in the table
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Prolonged infection or inflammation often leads to the
development of anemia (anemia of inflammation) and
there is a growing literature evaluating the effect of
vitamin D3 on inflammation [37]. However, our results
support the findings from a recent and large randomised
placebo-controlled trial that examined the impact of a 3-
month period of oral vitamin D supplementation on
circulating inflammatory markers in an African-American
cohort where vitamin D3 supplementation did not
affect CRP levels. [38]. Also, a meta-analysis of RCTs in
otherwise healthy individuals showed no effect of vita-
min D supplementation on CRP or other markers of
inflammation [39].
Furthermore, in patients with chronic kidney disease,
low levels of s-25(OH)D and 1,25-hydroxyvitamin D
(1,25(OH)D), the active form of vitamin D, were found
to be independently associated with decreased haemo-
globin levels and anaemia [17].
Additionally, marrow fibrosis has been reported in
cases of primary and secondary hyperparathyroidism
with very high levels of PTH. It has been suggested that
vitamin D improves anaemia only in those with very
high PTH levels and those with marrow fibrosis [40].
However, in our study, we did not find any correlation
between baseline s-ferritin or haemoglobin concentra-
tion and the levels of PTH. Observational studies show
associations that are indirectly due to poor diet is low in
both bioavailable iron and vitamin D. There are few
possible reasons for the lack of effect of vitamin D supple-
mentation on iron status in our study. Is it possible that
this study did not find any effects of vitamin D supple-
mentation on iron status because the bulk of the partici-
pants were relatively sufficient in iron and only a small
proportion of the participants had anaemia (n = 21). How-
ever, our sub-group analysis among the proportion with
anaemia the vitamin D3 supplementation had no effect on
iron status. Another possible explanation is that we don’t
have sufficient power to detect any changes because the
sample size was planned for an effect of the intervention
on muscle strength and power. It is also proposed that it
is likely that vitamin D improves anaemia only in those
with very high PTH and marrow fibrosis. In our study
over 30 % had PTH levels above the upper limit of the ref-
erence value at baseline, but effect of vitamin D supple-
mentation was not different than those with normal PTH.
Strengths and weaknesses
The strengths of this study included the following: it was
a strictly performed double-blind randomised placebo-
controlled trial, had good compliance and had relatively
high retention. Assessments were performed during the
winter and spring, at a time when sun exposure has little
impact on vitamin D synthesis, and all blood samples
were assayed in a single batch. The ethnic minorities tar-
geted in our study are known to have generally poor
vitamin D status. We measured the main iron status to
assess anaemia and iron deficiency anaemia. The study
also had some limitations. Although the vitamin D doses
used were sufficient to increase the s-25(OH)D levels,
the recommended level of 50 nmol/l was not reached in
43 % of the 25 μg supplementation group or in 62 % of
the 10 μg supplementation group. In addition, although
the analyses of iron markers were pre-planned, the study
was designed primarily to examine the outcomes on
muscular strength. We have not collected information
about the whole diet and therefore could not assess the
dietary intake of iron, vitamin B12 and folate.
Iron deficiency anaemia is the last end stage of progres-
sion from normal iron status to frank deficiency. Iron defi-
ciency reduces the work capacity of individuals and has
adverse effects on the immune system (high risk of infec-
tion) and several other chronic conditions [41–43]. Women
Table 3 Effect of intervention with 10 and 25 μg vitamin D3 supplementation on serum ferritin, hemoglobin, serum iron, Transferrin
saturation, folic acid and vitamin B12
Baselineb Final (after 16 weeks)b Difference in change (95 % CI)a
Placebo 10 μg 25 μg Placebo 10 μg 25 μg 10 μg 25 μg
S-25(OHD) (nmol/L) 29.2 (15.6) 30.7 (20.1) 26.8 (17.1) 27.5 (13.7) 45.9 (18.7) 51.1 (20.1) 17.5 (12.8, 22.1) 25.0 (20.4, 31.9)*
Hemoglobin (g/dL) 13.5 (1.4) 13.8 (1.7) 13.7 (1.4) 13.3 (1.4) 13.5 (1.6) 13.5 (1.6) -0.07 (-0.27, 0.14) -0.06 (-0.25, 0.1)
Serum ferritin (μg/L) 54.4 (63.2) 82.6 (92.5) 55.1 (57.2) 51.0 (57.8) 81.5 (106.2) 55.5 (58.0) 2.98 (-9.3, 15.3) 3.7 (-2.6, 9.9)
Serum iron (μg/L) 13.0 (5.9) 14.4 (5.9) 14.5 (5.8) 13.5 (6.7) 13.0 (5.5) 15.1 (6.4) -1.3.(-3.0, 0.5) -0.6 (-2.3, 1.0)
Transferrin saturation (%) 18.3 (.8.7) 21.7 (9.5) 20.9 (9.3) 18.7 (9.6) 19.3 (8.9) 21.7 (10.2) -1.3 (-3.9, 1.3) -1.0 (-3.4, 1.4)
S-Total iron binding
capacity (nmol/L)
73.2 (10.8) 68.7 (11.1) 71.7 (11.7) 73.5 (11.1) 69.4 (11.1) 72.1 (12.0) -0.23 (-2.2, 1.7) 0.2 (-1.6, 2.0)
S-Folic acid (nmol/L) 15.8 (5.8) 15.9 (6.6) 15.2 (7.1) 15.7 (6.1) 14.9 (7.1) 15.1 (7.3) -0.9 (-2.5, 0.7) -0.14 (-1.1, 0.8)
S-Vitamin B12 (pmol/L) 339.9 (105.5) 343.9 (116.8) 321.6 (92.7) 337.2 (118.9) 337.6 (132.7) 310 (89.5) -3.3 (-28.1, 21.5) -5.5 (-14.8, 3.9)
* p < 0.0001
adifference in change comparing to placebo and adjusted for baseline s-25(OH)D values
bData are mean (standard deviation) unless specified otherwise
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of reproductive age are at particularly high risk of iron defi-
ciency and its consequences. Therefore, a package of public
health measures addressing all aspects of iron deficiency,
anaemia and vitamin D deficiency are needed. The study
can be generalized to other immigrant populations in
Europe, but not necessarily to all ethnic groups or popula-
tions with anaemia and more research in populations with
anaemia is needed.
Conclusion
The main finding of this study was that supplementation
with vitamin D3 over 16 weeks did not improve serum
ferritin, haemoglobin, s-iron or transferrin saturation in
healthy adults. This study suggests that vitamin D
supplementation does not improve iron status for people
without anaemia.
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